Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5B
|
| pubmed:dateCreated |
1998-1-22
|
| pubmed:abstractText |
Animal experiments in BALB/c-mice and in DBA/2-mice confirmed that lectin blockade with D-galactose containing receptor analogues can inhibit metastatic spread into the liver. The number of liver colonies of inoculated tumor cells was significantly reduced after D-galactose treatment as compared to animals of control group. Based on experimental investigations 193 colorectal carcinoma patients (UICC stages I-III) were enrolled in a prospectively randomized clinical trial. 93 patients were treated perioperatively with D-galactose- (treatment group: 1.5 g/kg body weight and per day) or D-glucose containing electrolyte infusions (control group: n = 100). Significant side effects were not observed. There were no cases of perioperative mortality. The overall complication rate was 7.3%. Since tumor stages were unequally distributed, analysis was performed in strata. Patients were observed for a total of 6237 months. Differences in overall survival and survival free of recurrence and hepatic metastases were negligible for stages I and II. For stage III carcinoma patients (n = 75) analysis of survival free of hepatic metastases revealed a shift to delayed events (i.e. hepatic metastases or death) after D-galactose treatment within 24 months following surgery. In patients with stage III carcinoma there was an indication for an overall benefit in survival after D-galactose treatment (p = 0.102).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0250-7005
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3767-72
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9427777-Adult,
pubmed-meshheading:9427777-Aged,
pubmed-meshheading:9427777-Aged, 80 and over,
pubmed-meshheading:9427777-Animals,
pubmed-meshheading:9427777-Colonic Neoplasms,
pubmed-meshheading:9427777-Disease-Free Survival,
pubmed-meshheading:9427777-Female,
pubmed-meshheading:9427777-Galactose,
pubmed-meshheading:9427777-Humans,
pubmed-meshheading:9427777-Lectins,
pubmed-meshheading:9427777-Liver,
pubmed-meshheading:9427777-Liver Neoplasms,
pubmed-meshheading:9427777-Male,
pubmed-meshheading:9427777-Mice,
pubmed-meshheading:9427777-Mice, Inbred BALB C,
pubmed-meshheading:9427777-Mice, Inbred DBA,
pubmed-meshheading:9427777-Middle Aged,
pubmed-meshheading:9427777-Neoplasm Recurrence, Local,
pubmed-meshheading:9427777-Neoplasm Staging,
pubmed-meshheading:9427777-Prospective Studies,
pubmed-meshheading:9427777-Rectal Neoplasms
|
| pubmed:articleTitle |
Liver lectin blocking with D-galactose to prevent hepatic metastases in colorectal carcinoma patients.
|
| pubmed:affiliation |
Clinics and Policlinics for Surgery, University Cologne, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|